BridgeMD
A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients with IgAN
EU CTIS ID: 2025-521519-37-00
What this study is testing
Evaluate the effect of atacicept on Gd-IgA1 in patients with IgAN
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult male or female of ≥18 years of age, or as per country specific legally or nationally recognized adult age, who provides written informed consent prior to performing any study assessments
- Diagnosis of IgAN as demonstrated by renal biopsy with total urine protein excretion ≥0.75 g per 24-hour or UPCR ≥0.75 mg/mg based on a 24-hour urine sample, and eGFR ≥30 ml/min/1.73m2
- On a stable prescribed SoC regimen according to local practice listed in Section 4 of the protocol
- Systolic blood pressure ≤160 mmHg and diastolic blood pressure ≤90 mmHg at screening
You likely can't join if
- IgAN secondary to another condition or other causes of mesangial IgA deposition including IgA vasculitis, evidence of nephrotic syndrome within 6 months of screening, or concomitant chronic renal disease in addition to IgAN
- Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR within 3 months of screening)
- Active viral, bacterial or mycobacterial infections
- Existing conditions or clinically significant laboratory abnormalities that may interfere with participation in the study
- Administration of live and live-attenuated vaccinations within 30 days prior to randomization
- Known hypersensitivity to atacicept or any component of the formulated atacicept
The study team makes the final eligibility decision.
Where it's taking place
- Australia
- United States
- India
- Korea, Republic of
- Malaysia
- Philippines
- United Kingdom
- Turkey
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Australia; United States; India; Korea, Republic of; Malaysia; Philippines and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.